This article was reviewed by Jeffrey S. Heier, MD
This article was reviewed by Konstantin Petrukhin, PhD
This article was reviewed by Chirag D. Jhaveri, MD
This article was reviewed by Peter K. Kaiser, MD
Injection for leading cause of severe vision loss and legal blindness.
Researchers demonstrate the feasibility of a surgical method that specifically targets the area of geographic atrophy for RPE replacement.
A new class of IOL technology (EyeMax Mono) is tailored for patients with dry age-related macular degeneration (AMD).
Dr. Kaiser discusses how risuteganib fared in a phase II trial in patients with intermediate nonexudative AMD.
Eyes with persistent subretinal fluid fared better with visual acuity than eyes that were dry, according to the HARBOR Trial
ICYMI: Abicipar Phase II MAPLE Trial supports improved safety for patients with nAMD following a Modified Manufacturing Process